A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein tyrosine kinase receptor. The small-molecule tyrosine kinase receptor inhibitors (TKIs) are in clinical use to treat non-small cell lung cancer with EGFR mutations. Variable tumor responses to erlotinib and gefitinib have be...
Main Authors: | Nawazish A. Khan, Saied Mirshahidi, Hamid R. Mirshahidi |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2014-07-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/365325 |
Similar Items
-
Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer
by: Wensheng ZHOU, et al.
Published: (2020-02-01) -
The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01) -
Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer
by: Renhua GUO, et al.
Published: (2009-12-01) -
Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)
by: Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
Published: (2023-05-01) -
First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient
with EGFR Exon 20 Insertion Mutantion
by: Zhengguo LI, et al.
Published: (2024-03-01)